This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Liver Fibrosis Treatment Market

Market Insights on Liver Fibrosis Treatment covering sales outlook, demand forecast & up-to-date key trends

Liver Fibrosis Treatment Market by Treatment Type, Condition, End-use, Region & Forecast 2023 to 2033

Liver Fibrosis Treatment Market Snapshot (2023 to 2033)

The global liver fibrosis treatment market is expected to surpass an impressive valuation of US$ 16.43 billion in 2022 and is projected to exhibit a CAGR of 11% from 2022 to 2033. The primary factors of death and morbidity in individuals with liver cirrhosis are liver fibrosis and, in specific, cirrhosis. Their intervention or reversal has emerged as critical access points in clinical trials involving innovative liver-specific stimulants.

In persistent hepatitis B and C, significant advancements have been made with treatments that effectively address the consequence of fundamental liver damage. In the proportion of patients, extremely effective suppressive therapy can control strategies or even generate reversal, but this treatment remains elusive for the vast bulk of liver patients suffering from advanced alcoholic or nonalcoholic steatohepatitis, and genetic or immune deficiency liver failure.

Implementation for patients with liver fibrosis and personalized treatment is inextricably linked to the emergence of noninvasive fibrosis, fibrogenesis, and fibrosis biomarkers, which will continue to lead the industry. Cirrhosis is the 12th primary factor of death in the United States. Latest research has shown that liver fibrosis is a continual process and that initial cirrhosis may be recoverable. As a result, the treatment for liver fibrosis is expected to grow significantly over the next decades. Although liver biopsy is still the fundamental basis, transient elastography has become increasingly widely available and is quickly replacing biopsy as the preferred option for liver fibrosis staging which is contributing to the market expansion.

Furthermore, rising cancer cases, including liver cancer, are anticipated to propel the expansion of the global chronic liver disease therapeutic industry, contributing to market growth. For instance, the American Cancer Society estimates that 41,260 suspected cases of primary liver cancer were diagnosed in the United States in 2022 (28,600 in men and 12,660 in women).

Rising the number of various forms of chronic liver diseases is driving the market growth. For instance, Primary Sclerosing Cholangitis (PSC) is a chronic illness in which the bile ducts inside and outside the liver get to be sore and disfigured, ultimately narrowing and blocking, and causing liver damage. Based on the National Institute of Health, nonalcoholic fatty liver disease (NAFLD) represents the most prevalent liver disease, accounting for 25% of all cases worldwide. NAFLD and its variant, nonalcoholic steatohepatitis, influence 30% and 5% of the people in the United States, respectively. Therefore, treatment for liver fibrosis is expected to grow significantly in this country.

Hepatitis C therapeutics are becoming more widely used among healthcare professionals in the United States, and a growing number of patients are receiving them. This, integrated with a robust R&D pipeline and the introduction of novel medicines in the United States, is accelerating the expansion of the hepatitis C treatment marketplace in North America. For instance, in April 2019, the US Food and Drug Administration approved Mavyret by AbbVie as the first-ever treatment affirmed for pediatric Hepatitis C patients of all genotypes. As a result of these factors, the Liver Fibrosis Treatment Market is expected to grow in the coming decades.

The high incidence of Nonalcoholic steatohepatitis (NASH) also affects the population, fueling the market growth. NASH affects approximately 3% to 6% of the US inhabitants, and the pervasiveness is rising. Although there are several noninvasive screening and rating systems available to characterize NAFLD and NASH, liver biopsy is the only acceptable form for diagnosing NASH. Presently, the US Food and Drug Administration has not approved any NASH-specific therapies.

Data Points

Key Statistics

Expected Market Value (2022)

US$ 16.43 billion

Anticipated Forecast Value (2033)

US$ 46.65 billion

Projected Growth Rate (2022 to 2033)

11% CAGR

Customize this Report

Let us know your requirement to get
100% FREE customization

2018 to 2022 Liver Fibrosis Treatment Demand Analysis vs. Forecast 2022 to 2033

The COVID-19 pandemic had an adverse effect on the global liver fibrosis therapeutics market, as the demand for medications used in liver rehabilitation decreased. Based on the National Center for Biotechnology Information, COVID-19 therapy in January 2020 involves discussing and parenterally administered agents, antivirals, immunomodulatory medicines, anti-cytokines, monoclonal antibodies, and miscellaneous agents. As a result, drugs demonstrated for use in other disease conditions have been produced in smaller quantities than those used in COVID-19 treatment. From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 3%.

The rise in the prevalence of adverse outcomes such as patients with hepatitis B or C virus infection, a suppressed immune system owing to co-infection with human immunodeficiency virus (HIV), and the usage of immunosuppressive medicines after a liver transplant are poised to drive growth in the liver fibrosis treatment market over the forecast period. For instance, as per World Health Organization data released in 2022, 296 million individuals were estimated to be residing with chronic hepatitis B infection in 2019, with 1.5 million new infections each year. Hepatitis B caused an estimated 820 000 deaths in 2019, the majority of which were caused by cirrhosis and hepatocellular carcinoma.

Which are Some Prominent Drivers of the Liver Fibrosis Treatment Market?

Funding Approaches by multiple private research organizations to Drive Market

The increased research carried out by several private research organizations to develop treatments for liver fibrosis and other fatty liver diseases are anticipated to increase growth in the liver fibrosis treatment market. For instance, in August 2018, Virginia Tech's College of Science and the University of Virginia's Department of Pharmacology garnered US$400,000 in funding from the Virginia Biosciences Health Research Corporation (VBHRC), with Continuum Biosciences, Inc. matching funds. This grant, combined with matching funds, would assist scientists in creating drugs to treat nonalcoholic steatohepatitis (NASH).

Research and studies to evolve novel treatment therapies in liver fibrosis disease drive market growth

Expanding pre-clinical and clinical studies and development by prominent stakeholders to establish innovative treatment options in the liver fibrosis regime are predicted to propel the worldwide liver fibrosis treatment's future growth. For instance, the US Food and Drug Administration permitted Orphan Drug Designation to PTG-300, a subcutaneous injectable evolved by Protagonist Therapeutics, Inc., in March 2018. The PTG-300 is presently in a medical study for the treatment of beta-thalassemia and can also be employed to cure liver fibrosis.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Challenges Projected to be Faced by the Market?

High Costs to Hinder Market Growth

The massive cost necessary for drug assessment of the liver disease therapeutic process is one of the key factors impeding the expansion of the global liver fibrosis treatment market. According to the Centers for Disease Analysis, the United States invests $5 billion per year on disease-related healthcare costs like chemotherapy, transplants, screening, and hospitalizations.

Region-Wise Insights

What Makes North America the Largest Market for Liver Fibrosis Treatment?

The accessibility of a variety of Innovative Drug Molecules drive Asia Pacific market

Owing to the availability of a variety of novel drug molecules to improve the treatment process and technological development in rehabilitation in this region, North America leads the liver fibrosis market. Furthermore, surging medical spending and the emergence of major important players will speed up the market's pace of growth in this region. The mortality rate from liver diseases has increased, as has the occurrence of liver cancer.

Non-alcoholic fatty liver disorder (NAFLD) affects approximately 20% of Canadians, based on the Canadian Liver Foundation. Obesity is the primary factor of fatty liver disease in Canada. In 2018, nearly 30% of Canadians aged 18 and up reported being overweight or obese based on their height and weight.

Why is Asia Pacific Considered a Lucrative Region for the Liver Fibrosis Treatment Market?

Increasing Prevalence of Liver Fibrosis is Spurring Demand for Liver Fibrosis Treatment

Asia Pacific is predicted to expand during the forthcoming years owing to the rising incidence of liver fibrosis in this region. Moreover, the advancement of medical infrastructure and soaring regulatory reforms will enhance the industry's pace of growth in this region. During the projected period, the Asia Pacific market is projected to show the highest CAGR of 11.1%.

There is a growing patient pool of hepatitis C patients in developing nations like China, India, and other South-East Asian countries. Nevertheless, the patient population is dependent on the various governments for subsidized drugs, and earnings contribution is lesser; moreover, due to such aspects, the market in the Asia Pacific is growing rapidly.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Category-Wise Insights

By End-User, Which Segment is Projected to Lead the Market?

Hospital Segment is Estimated to Hold the Largest Share

Based on end user, the global liver fibrosis treatment market is segmented into hospital, and Specialty Clinics. The hospital segment held the largest share of the market in 2021. Moreover, the same segment is expected to register the highest CAGR from 2022 to 2033.

Which Treatment Type Segment to Grow Rapidly?

Hepatotropic drug segment led the market in historical period

With a market share of 29.5% in 2021, the hepatotropic drug segment led the market. This increase is attributed to increased awareness of new drugs. Furthermore, hepatitis is a medical condition that primarily affects the liver, eventually contaminating the digestion process and the brain. HCV, HBV, and HAV are the three major types of hepatitis conditions. HCV is a major public health problem in which the liver becomes inflamed as a result of infection. As a result, this segment is expected to grow rapidly.

Start Ups offering Liver Fibrosis Treatment

  • Beijing Continent Pharmaceutical Co, Ltd., a pharmacological firm started in 2002, completed an effective Phase II clinical trial for Hydronidone capsules in December 2021 and was enhanced to a Phase 3 clinical trial in January 2022. The phase 3 clinical trial experiments for Hydronidone capsules are still continuing and are anticipated to be completed in June 2024.
  • HepC is a developer of antibacterial pharmacologic products that was established in 2005. IBDV, a non-pathogenic double-stranded RNA virus, is used by the organization. As its foremost vector scheme, this virus behaves as an expert inducer of antiviral gene reactions. It is developing HC001 to cure chronic viral hepatitis caused by HBV and HCV infections.

Market Competition

Key players in the Liver Fibrosis Treatment market are Gilead Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Johnson and Johnson, Novartis AG, Vertex Pharmaceuticals Incorporated, Pfizer Inc., FibroGen, Inc., Inventiva Pharma, Pharmaxis Limited.

  • In March 2019, Gilead Sciences Inc. launched the HepConnect Program to Reduce Hepatitis C Infections in Greater Appalachia.
  • It was disclosed in December 2020 that Aligos Therapeutics Inc. will collaborate with Merck & Co. Inc. to create a therapy for liver fibrosis treatment.

Report Scope

Report Attribute

Details

Market Value in 2022

US$ 2.5 billion

Market Value in 2033

US$ 46.65 billion

Growth Rate

CAGR of 11% from 2022 to 2033

Base Year for Estimation

2022

Historical Data

2018 to 2022

Forecast Period

2022 to 2033

Quantitative Units

Revenue in US$ Billion and CAGR from 2022 to 2033

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Treatment Type
  • Condition
  • End User
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Key Countries Profiled

  • USA
  • Canada
  • Brazil
  • Mexico
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel

Key Companies Profiled

  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb
  • Johnson and Johnson
  • Novartis AG
  • Vertex Pharmaceuticals Incorporated
  • Pfizer Inc.
  • FibroGen, Inc.
  • Inventiva Pharma
  • Pharmaxis Limited

Customization

Available Upon Request

Key Segments Profiled in the Liver Fibrosis Treatment Industry Survey

By Treatment Type:

  • Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
  • ACE Inhibitors
  • Hepatotropic Drug
  • Others

By Condition:

  • Chronic Liver Diseases
  • Hepatitis C
  • Nonalcoholic Steatohepatitis

By End User:

  • Hospitals
  • Specialty Clinics
  • Others

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Frequently Asked Questions

FMI projects the global Liver Fibrosis Treatment market to expand at an 11% value CAGR by 2033.

The global Liver Fibrosis Treatment market is estimated at a market value of US$ 16.43 Billion.

The global Liver Fibrosis Treatment market is expected to garner a market value of US$ 46.65 Billion.

FMI has projected North America to be one of the key regions for the Liver Fibrosis Treatment market.

Gilead Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Johnson and Johnson, Novartis AG, Vertex Pharmaceuticals Incorporated, Pfizer Inc., FibroGen, Inc., Inventiva Pharma, Pharmaxis Limited

Table of Content

1. Executive Summary | Liver Fibrosis Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033

        5.3.1. Peroxisome Proliferator-activated Receptors (PPAR)-alpha Agonist

        5.3.2. ACE Inhibitors

        5.3.3. Hepatotropic Drug

        5.3.4. Others

    5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Condition

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Condition, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Condition, 2023 to 2033

        6.3.1. Chronic Liver Diseases

        6.3.2. Hepatitis C

        6.3.3. Nonalcoholic Steatohepatitis

    6.4. Y-o-Y Growth Trend Analysis By Condition, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Condition, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By End User , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User , 2023 to 2033

        7.3.1. Hospitals

        7.3.2. Specialty Clinics

        7.3.3. Others

    7.4. Y-o-Y Growth Trend Analysis By End User , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By End User , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Treatment Type

        9.2.3. By Condition

        9.2.4. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Treatment Type

        9.3.3. By Condition

        9.3.4. By End User

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Treatment Type

        10.2.3. By Condition

        10.2.4. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Treatment Type

        10.3.3. By Condition

        10.3.4. By End User

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Treatment Type

        11.2.3. By Condition

        11.2.4. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Treatment Type

        11.3.3. By Condition

        11.3.4. By End User

    11.4. Key Takeaways

12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

            12.2.1.4. Singapore

            12.2.1.5. Thailand

            12.2.1.6. Indonesia

            12.2.1.7. Australia

            12.2.1.8. New Zealand

            12.2.1.9. Rest of Asia Pacific

        12.2.2. By Treatment Type

        12.2.3. By Condition

        12.2.4. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Treatment Type

        12.3.3. By Condition

        12.3.4. By End User

    12.4. Key Takeaways

13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of MEA

        13.2.2. By Treatment Type

        13.2.3. By Condition

        13.2.4. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Treatment Type

        13.3.3. By Condition

        13.3.4. By End User

    13.4. Key Takeaways

14. Key Countries Market Analysis

    14.1. USA

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2022

            14.1.2.1. By Treatment Type

            14.1.2.2. By Condition

            14.1.2.3. By End User

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2022

            14.2.2.1. By Treatment Type

            14.2.2.2. By Condition

            14.2.2.3. By End User

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2022

            14.3.2.1. By Treatment Type

            14.3.2.2. By Condition

            14.3.2.3. By End User

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2022

            14.4.2.1. By Treatment Type

            14.4.2.2. By Condition

            14.4.2.3. By End User

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2022

            14.5.2.1. By Treatment Type

            14.5.2.2. By Condition

            14.5.2.3. By End User

    14.6. United Kingdom

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2022

            14.6.2.1. By Treatment Type

            14.6.2.2. By Condition

            14.6.2.3. By End User

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2022

            14.7.2.1. By Treatment Type

            14.7.2.2. By Condition

            14.7.2.3. By End User

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2022

            14.8.2.1. By Treatment Type

            14.8.2.2. By Condition

            14.8.2.3. By End User

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2022

            14.9.2.1. By Treatment Type

            14.9.2.2. By Condition

            14.9.2.3. By End User

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2022

            14.10.2.1. By Treatment Type

            14.10.2.2. By Condition

            14.10.2.3. By End User

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2022

            14.11.2.1. By Treatment Type

            14.11.2.2. By Condition

            14.11.2.3. By End User

    14.12. South Korea

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2022

            14.12.2.1. By Treatment Type

            14.12.2.2. By Condition

            14.12.2.3. By End User

    14.13. Singapore

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2022

            14.13.2.1. By Treatment Type

            14.13.2.2. By Condition

            14.13.2.3. By End User

    14.14. Thailand

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2022

            14.14.2.1. By Treatment Type

            14.14.2.2. By Condition

            14.14.2.3. By End User

    14.15. Indonesia

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2022

            14.15.2.1. By Treatment Type

            14.15.2.2. By Condition

            14.15.2.3. By End User

    14.16. Australia

        14.16.1. Pricing Analysis

        14.16.2. Market Share Analysis, 2022

            14.16.2.1. By Treatment Type

            14.16.2.2. By Condition

            14.16.2.3. By End User

    14.17. New Zealand

        14.17.1. Pricing Analysis

        14.17.2. Market Share Analysis, 2022

            14.17.2.1. By Treatment Type

            14.17.2.2. By Condition

            14.17.2.3. By End User

    14.18. GCC Countries

        14.18.1. Pricing Analysis

        14.18.2. Market Share Analysis, 2022

            14.18.2.1. By Treatment Type

            14.18.2.2. By Condition

            14.18.2.3. By End User

    14.19. South Africa

        14.19.1. Pricing Analysis

        14.19.2. Market Share Analysis, 2022

            14.19.2.1. By Treatment Type

            14.19.2.2. By Condition

            14.19.2.3. By End User

    14.20. Israel

        14.20.1. Pricing Analysis

        14.20.2. Market Share Analysis, 2022

            14.20.2.1. By Treatment Type

            14.20.2.2. By Condition

            14.20.2.3. By End User

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Treatment Type

        15.3.3. By Condition

        15.3.4. By End User

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. Gilead Sciences, Inc.

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. Merck & Co., Inc.

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. Bristol-Myers Squibb

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. Johnson and Johnson

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. Novartis AG

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. Vertex Pharmaceuticals Incorporated

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. Pfizer Inc.

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. FibroGen, Inc.

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. Inventiva Pharma

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. Pharmaxis Limited.

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Condition, 2018 to 2033

Table 4: Global Market Value (US$ Million) Forecast by End User , 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Condition, 2018 to 2033

Table 8: North America Market Value (US$ Million) Forecast by End User , 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Latin America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Condition, 2018 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by End User , 2018 to 2033

Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Europe Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 15: Europe Market Value (US$ Million) Forecast by Condition, 2018 to 2033

Table 16: Europe Market Value (US$ Million) Forecast by End User , 2018 to 2033

Table 17: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 18: Asia Pacific Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 19: Asia Pacific Market Value (US$ Million) Forecast by Condition, 2018 to 2033

Table 20: Asia Pacific Market Value (US$ Million) Forecast by End User , 2018 to 2033

Table 21: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: MEA Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 23: MEA Market Value (US$ Million) Forecast by Condition, 2018 to 2033

Table 24: MEA Market Value (US$ Million) Forecast by End User , 2018 to 2033

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Condition, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by End User , 2023 to 2033

Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 11: Global Market Value (US$ Million) Analysis by Condition, 2018 to 2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Condition, 2023 to 2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Condition, 2023 to 2033

Figure 14: Global Market Value (US$ Million) Analysis by End User , 2018 to 2033

Figure 15: Global Market Value Share (%) and BPS Analysis by End User , 2023 to 2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by End User , 2023 to 2033

Figure 17: Global Market Attractiveness by Treatment Type, 2023 to 2033

Figure 18: Global Market Attractiveness by Condition, 2023 to 2033

Figure 19: Global Market Attractiveness by End User , 2023 to 2033

Figure 20: Global Market Attractiveness by Region, 2023 to 2033

Figure 21: North America Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 22: North America Market Value (US$ Million) by Condition, 2023 to 2033

Figure 23: North America Market Value (US$ Million) by End User , 2023 to 2033

Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by Condition, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Condition, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Condition, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by End User , 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by End User , 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by End User , 2023 to 2033

Figure 37: North America Market Attractiveness by Treatment Type, 2023 to 2033

Figure 38: North America Market Attractiveness by Condition, 2023 to 2033

Figure 39: North America Market Attractiveness by End User , 2023 to 2033

Figure 40: North America Market Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 42: Latin America Market Value (US$ Million) by Condition, 2023 to 2033

Figure 43: Latin America Market Value (US$ Million) by End User , 2023 to 2033

Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) Analysis by Condition, 2018 to 2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Condition, 2023 to 2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Condition, 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) Analysis by End User , 2018 to 2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User , 2023 to 2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User , 2023 to 2033

Figure 57: Latin America Market Attractiveness by Treatment Type, 2023 to 2033

Figure 58: Latin America Market Attractiveness by Condition, 2023 to 2033

Figure 59: Latin America Market Attractiveness by End User , 2023 to 2033

Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 61: Europe Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 62: Europe Market Value (US$ Million) by Condition, 2023 to 2033

Figure 63: Europe Market Value (US$ Million) by End User , 2023 to 2033

Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Europe Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 69: Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 70: Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 71: Europe Market Value (US$ Million) Analysis by Condition, 2018 to 2033

Figure 72: Europe Market Value Share (%) and BPS Analysis by Condition, 2023 to 2033

Figure 73: Europe Market Y-o-Y Growth (%) Projections by Condition, 2023 to 2033

Figure 74: Europe Market Value (US$ Million) Analysis by End User , 2018 to 2033

Figure 75: Europe Market Value Share (%) and BPS Analysis by End User , 2023 to 2033

Figure 76: Europe Market Y-o-Y Growth (%) Projections by End User , 2023 to 2033

Figure 77: Europe Market Attractiveness by Treatment Type, 2023 to 2033

Figure 78: Europe Market Attractiveness by Condition, 2023 to 2033

Figure 79: Europe Market Attractiveness by End User , 2023 to 2033

Figure 80: Europe Market Attractiveness by Country, 2023 to 2033

Figure 81: Asia Pacific Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 82: Asia Pacific Market Value (US$ Million) by Condition, 2023 to 2033

Figure 83: Asia Pacific Market Value (US$ Million) by End User , 2023 to 2033

Figure 84: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 85: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: Asia Pacific Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 91: Asia Pacific Market Value (US$ Million) Analysis by Condition, 2018 to 2033

Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Condition, 2023 to 2033

Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Condition, 2023 to 2033

Figure 94: Asia Pacific Market Value (US$ Million) Analysis by End User , 2018 to 2033

Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by End User , 2023 to 2033

Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by End User , 2023 to 2033

Figure 97: Asia Pacific Market Attractiveness by Treatment Type, 2023 to 2033

Figure 98: Asia Pacific Market Attractiveness by Condition, 2023 to 2033

Figure 99: Asia Pacific Market Attractiveness by End User , 2023 to 2033

Figure 100: Asia Pacific Market Attractiveness by Country, 2023 to 2033

Figure 101: MEA Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 102: MEA Market Value (US$ Million) by Condition, 2023 to 2033

Figure 103: MEA Market Value (US$ Million) by End User , 2023 to 2033

Figure 104: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 105: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 106: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: MEA Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 109: MEA Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 110: MEA Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 111: MEA Market Value (US$ Million) Analysis by Condition, 2018 to 2033

Figure 112: MEA Market Value Share (%) and BPS Analysis by Condition, 2023 to 2033

Figure 113: MEA Market Y-o-Y Growth (%) Projections by Condition, 2023 to 2033

Figure 114: MEA Market Value (US$ Million) Analysis by End User , 2018 to 2033

Figure 115: MEA Market Value Share (%) and BPS Analysis by End User , 2023 to 2033

Figure 116: MEA Market Y-o-Y Growth (%) Projections by End User , 2023 to 2033

Figure 117: MEA Market Attractiveness by Treatment Type, 2023 to 2033

Figure 118: MEA Market Attractiveness by Condition, 2023 to 2033

Figure 119: MEA Market Attractiveness by End User , 2023 to 2033

Figure 120: MEA Market Attractiveness by Country, 2023 to 2033

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Pancreatic Cancer Market

Published : December 2022

Healthcare

Liver Fluke Treatment Market

Published : April 2019

Food and Beverage

Liver Health Supplements Market

Published : March 2019

Healthcare

Liver Transplantation Market

Published : March 2016

Google translate

Liver Fibrosis Treatment Market